These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910 [TBL] [Abstract][Full Text] [Related]
23. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports. Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292 [TBL] [Abstract][Full Text] [Related]
24. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization. O'Neill RT Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506 [TBL] [Abstract][Full Text] [Related]
25. Pharmacovigilance and communicating safety information. Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564 [TBL] [Abstract][Full Text] [Related]
26. Pharmacoepidemiology and its input to pharmacovigilance. Faillie JL; Montastruc F; Montastruc JL; Pariente A Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840 [TBL] [Abstract][Full Text] [Related]
27. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses. Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117 [TBL] [Abstract][Full Text] [Related]
28. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016. Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556 [TBL] [Abstract][Full Text] [Related]
29. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns. Holm JEJ; Ruppert JG; Ramsden SD Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785 [TBL] [Abstract][Full Text] [Related]
30. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes. Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834 [TBL] [Abstract][Full Text] [Related]
31. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
32. c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper. Aurich B; Apele-Freimane D; Banaschewski T; Chouchana L; Day S; Kaguelidou F; Kelly LE; Kindblom JM; Neubert A; Wong ICK Br J Clin Pharmacol; 2022 Dec; 88(12):4997-5016. PubMed ID: 34699077 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758 [TBL] [Abstract][Full Text] [Related]
34. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics. Kaguelidou F; Durrieu G; Clavenna A Therapie; 2019 Apr; 74(2):315-324. PubMed ID: 30773345 [TBL] [Abstract][Full Text] [Related]
35. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. Lu CY Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976 [TBL] [Abstract][Full Text] [Related]
36. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries. Shani S; Yahalom Z Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669 [No Abstract] [Full Text] [Related]
37. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans. Piana C; Kliphuis E; Della Pasqua O Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676 [TBL] [Abstract][Full Text] [Related]
38. Biosimilars: pharmacovigilance and risk management. Zuñiga L; Calvo B Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204 [TBL] [Abstract][Full Text] [Related]
39. [Benefits of large healthcare databases for drug risk research]. Garbe E; Pigeot I Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Aug; 58(8):829-837. PubMed ID: 26092163 [TBL] [Abstract][Full Text] [Related]
40. [The new pharmacovigilance legislation in practice]. Broekmans AW; Mol PG Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]